Neuroleptic malignant syndrome

Source: Wikipedia, the free encyclopedia.
Neuroleptic malignant syndrome
lethal catatonia[2]
TreatmentStopping the offending medication, rapid cooling, starting other medications[2]
MedicationDantrolene, bromocriptine, diazepam[2]
Prognosis10–15% risk of death[4]
Frequency15 per 100,000 per year (on neuroleptics)[1]

Neuroleptic malignant syndrome (NMS) is a rare

seizures.[1][2]

Any medications within the family of antipsychotics can cause the condition, though

first generation antipsychotics like haloperidol.[5] Onset is often within a few weeks of starting the medication but can occur at any time.[1][3] Risk factors include dehydration, agitation, and catatonia.[4]

Rapidly decreasing the use of

dopamine receptors.[1] Diagnosis is based on symptoms.[2]

Management includes stopping the triggering medication, rapid cooling, and starting other medications.[2] Medications used include dantrolene, bromocriptine, and diazepam.[2] The risk of death among those affected is about 10%.[4] Rapid diagnosis and treatment is required to improve outcomes.[1] Many people can eventually be restarted on a lower dose of antipsychotic.[2][3]

As of 2011, among those in

psychiatric hospitals on antipsychotics about 15 per 100,000 are affected per year (0.015%).[1] In the second half of the 20th century rates were over 100 times higher at about 2% (2,000 per 100,000).[1] Males appear to be more often affected than females.[1] The condition was first described in 1956.[1]

Signs and symptoms

NMS symptoms include:[8]

  • Increased body temperature >38 °C (>100.4 °F), or
  • Confused or altered consciousness[9]
  • Excessive sweating[9]
  • Rigid muscles[8]
  • Autonomic imbalance[8]

The first symptoms of neuroleptic malignant syndrome are usually

muscle cramps and tremors, fever, symptoms of autonomic nervous system instability such as unstable blood pressure, and sudden changes in mental status (agitation, delirium, or coma). Once symptoms appear, they may progress rapidly and reach peak intensity in as little as three days.[8] These symptoms can last anywhere from eight hours to forty days.[4]

Symptoms are sometimes misinterpreted by doctors as symptoms of mental illness which can result in delayed treatment.[10] NMS is less likely if a person has previously been stable for a period of time on antipsychotics, especially in situations where the dose has not been changed and there are no issues of noncompliance or consumption of psychoactive substances known to worsen psychosis.[citation needed]

Causes

NMS is usually caused by antipsychotic drug use, and a wide range of drugs can result in NMS.[11] Individuals using butyrophenones (such as haloperidol and droperidol) or phenothiazines (such as promethazine and chlorpromazine) are reported to be at greatest risk. However, various atypical antipsychotics such as clozapine, olanzapine, risperidone, quetiapine, and ziprasidone have also been implicated in cases.[12]

NMS may also occur in people taking

dothiepin, phenelzine, tetrabenazine, and reserpine have been known to trigger NMS.[15] Whether lithium can cause NMS is unclear.[16] However, concomitant use of lithium is associated with a higher risk of NMS when the patient starts on a antipsychotic drug.[17]

At the molecular level, NMS is caused by a sudden, marked reduction in dopamine activity, either from withdrawal of dopaminergic agents or from blockade of dopamine receptors.[18]

Risk factors

One of the clearest risk factors in the development of NMS is the course of drug therapy chosen to treat a condition. Use of high-potency antipsychotics, a rapid increase in the dosage of antipsychotics, and use of long-acting forms of antipsychotics (such as haloperidol) [19] are all known to increase the risk of developing NMS.[20] There appears to be no relationship between duration of therapy and the development of NMS.[6]

Use of the following agents is most commonly associated with the development of NMS:[8]

  • Typical antipsychotics: e.g. haloperidol, chlorpromazine.[21]
  • Atypical antipsychotics: e.g. olanzapine, clozapine, risperidone
  • Anti-dopaminergic antiemetics: e.g. droperidol
  • Withdrawal of dopaminergic agents: e.g.
    levodopa, amantadine[22]

It has been purported that there is a genetic risk factor for NMS.[23] In one study, identical twins presented with NMS, and a mother and two of her daughters have presented with NMS in another case.[24]

Demographically, it appears that males, especially those under forty, are at greatest risk for developing NMS, although it is unclear if the increased incidence is a result of greater antipsychotic use in men under forty.[11] It has also been suggested that postpartum women may be at a greater risk for NMS.[25]

An important risk factor for this condition is Lewy body dementia. These patients are extremely sensitive to antipsychotics. As a result, antipsychotics should be used cautiously in all cases of dementia.[26]

Pathophysiology

The mechanism is commonly thought to depend on decreased levels of dopamine activity due to:

  • Dopamine receptor blockade
  • Genetically reduced function of dopamine receptor D2[27]
  • Sympathoadrenal hyperactivity and autonomic dysfunction

It has been proposed that blockade of D2-like (D2, D3 and D4) receptors induce massive glutamate release, generating catatonia, neurotoxicity and myotoxicity.[28][29] Additionally, the blockade of diverse serotonin receptors by atypical antipsychotics and activation of 5-HT1 receptors by certain of them reduces GABA release and indirectly induces glutamate release, worsening this syndrome.[30]

The muscular symptoms are most likely caused by blockade of the dopamine receptor D2, leading to abnormal function of the basal ganglia similar to that seen in Parkinson's disease.[31]

In the past, research and clinical studies seemed to corroborate the D2 receptor blockade theory in which antipsychotic drugs were thought to significantly reduce dopamine activity by blocking the D2 receptors associated with this neurotransmitter. The introduction of atypical antipsychotic drugs, with lower affinity to the D2 dopamine receptors, was thought to have reduced the incidence of NMS. However, recent studies suggest that the decrease in mortality may be the result of increased physician awareness and earlier initiation of treatment rather than the action of the drugs themselves.[32] NMS induced by atypical drugs also resembles "classical" NMS (induced by "typical" antipsychotic drugs), further casting doubt on the overall superiority of these drugs.[33]

However, the failure of D2 dopamine receptor antagonism, or dopamine receptor dysfunction, do not fully explain the presenting symptoms and signs of NMS, as well as the occurrence of NMS with

typical antipsychotics, are known to block dopamine receptors; other studies have shown that when drugs supplying dopamine are withdrawn, symptoms similar to NMS present themselves.[4]

In support of the sympathoadrenal hyperactivity model, it has been hypothesized that a defect in calcium regulatory proteins within the sympathetic neurons may bring about the onset of NMS.[35] This model of NMS strengthens its suspected association with malignant hyperthermia in which NMS may be regarded as a neurogenic form of this condition which itself is linked to defective calcium-related proteins.[citation needed]

There is also thought to be considerable overlap between malignant catatonia and NMS in their pathophysiology, the former being idiopathic and the latter being the drug-induced form of the same syndrome.[36]

The

EEG is reported in around 50% of cases.[citation needed
]

The fever seen with NMS is believed to be caused by hypothalamic dopamine receptor blockade. The peripheral problems (the high white blood cell and CPK count) are caused by the antipsychotic drugs. They cause an increased calcium release from the

EEG, but it is likely also attributable to dopamine blockage leading to changes in neuronal pathways.[11]

Diagnosis

Differential diagnosis

Due to the comparative rarity of NMS, it is often overlooked. Immediate treatment for the syndrome should not be delayed as it has a high mortality of between 10-20%.[38] Differentiating NMS from other neurological disorders can be very difficult. It requires expert judgement to separate symptoms of NMS from other diseases.

The diagnosis is suggested on patients with an accurate history of drug exposure to the most common inducing agents such as strong antidopaminergic medication.

bradykinesia, muscle rigidity, and a high white blood cell count.[42]

Treatment

NMS is a medical emergency and can lead to death if untreated. The first step is to stop the antipsychotic medication and treat the hyperthermia aggressively, such as with cooling blankets or ice packs to the axillae and groin. Supportive care in an intensive care unit capable of circulatory and ventilatory support is crucial. The best pharmacological treatment is still unclear. Dantrolene has been used when needed to reduce muscle rigidity, and more recently dopamine pathway medications such as bromocriptine have shown benefit.[43] Amantadine is another treatment option due to its dopaminergic and anticholinergic effects. Apomorphine may be used however its use is supported by little evidence.[31] Benzodiazepines may be used to control agitation. Highly elevated blood myoglobin levels can result in kidney damage, therefore aggressive intravenous hydration with diuresis may be required. When recognized early NMS can be successfully managed; however, up to 10% of cases can be fatal.[4]

Should the affected person subsequently require an antipsychotic, trialing a low dose of a low-potency atypical antipsychotic is recommended.[4]

Prognosis

The prognosis is best when identified early and treated aggressively. In these cases NMS is not usually fatal. In earlier studies the mortality rates from NMS ranged from 20%–38%, but by 2009 mortality rates were reported to have fallen below 10% over the previous two decades due to early recognition and improved management.[44] Re-introduction to the drug that originally caused NMS to develop may also trigger a recurrence, although in most cases it does not.[citation needed]

Memory impairment is a consistent feature of recovery from NMS, and is usually temporary though in some cases may become persistent.[45]

Epidemiology

Pooled data suggest the incidence of NMS is between 0.2%–3.23%.[46] However, greater physician awareness coupled with increased use of atypical anti-psychotics have likely reduced the prevalence of NMS.[11] Additionally, young males are particularly susceptible and the male:female ratio has been reported to be as high as 2:1.[11][46][47]

History

NMS was known about as early as 1956, shortly after the introduction of the first phenothiazines.[48][self-published source?] NMS was first described in 1960 by French clinicians who had been working on a study involving haloperidol. They characterized the condition that was associated with the side effects of haloperidol "syndrome malin des neuroleptiques", which was translated to neuroleptic malignant syndrome.[15]

References

  1. ^
    PMID 23983836
    .
  2. ^ a b c d e f g h i j "Neuroleptic Malignant Syndrome". NORD (National Organization for Rare Disorders). 2004. Archived from the original on 19 February 2017. Retrieved 1 July 2017.
  3. ^ a b c "Neuroleptic Malignant Syndrome Information Page". Bethesda, Maryland: National Institute of Neurological Disorders and Stroke. Archived from the original on 4 July 2017. Retrieved 1 July 2017.
  4. ^
    PMID 17541044
    .
  5. ^
    PMID 26484986
    .
  6. ^
    S2CID 43859486
    .
  7. PMID 29464217
    .
  8. ^
    PMID 29489248
    .
  9. ^ a b Papadakis MA, McPhee SJ (2023). "Neuroleptic malignant syndrome.". Quick Medical Diagnosis & Treatment. McGraw Hill.
  10. ^ Milbouer S. "Quest for the truth". Nashua Telegraph. Archived from the original on 2007-09-27.
  11. ^ a b c d e Neuroleptic Malignant Syndrome at eMedicine
  12. PMID 19081460
    .
  13. PMID 1672810
    .
  14. PMID 3632154
    .
  15. ^
    PMID 7897404
    .
  16. ISBN 978-0-444-53716-4
    .
  17. PMID 7897404
    .
  18. ^ "Treatment of Schizophrenia". TMedWeb: Medical Pharmacology. Tulane University. Retrieved 2021-06-19.
  19. ISBN 978-0-07-184313-3
    .
  20. PMID 2572206
    .
  21. ISBN 978-1-260-47007-9
    .
  22. ISBN 978-1-260-47379-7
    .
  23. S2CID 23303714
    .
  24. S2CID 23185221
    .
  25. PMID 9632037
    .
  26. PMID 22952071
    .
  27. S2CID 44866985
    .
  28. S2CID 45530847
    .
  29. PMID 24753679
    .
  30. PMID 19149529
    .
  31. ^ a b Wijdicks EF (26 May 2022). Aminoff MJ, Rabinstein AA, Wilterdink JL (eds.). "Neuroleptic malignant syndrome". UpToDate.
  32. ^
    S2CID 32752143
    .
  33. PMID 9699705
    .
  34. S2CID 31276121
    .
  35. S2CID 29010904
    .
  36. S2CID 12971112
    .
  37. PMID 18687233. Archived
    from the original on 2016-06-01.
  38. ISBN 978-1-259-86107-9
    .
  39. ISBN 978-0-07-173881-1
    .
  40. PMID 11219110
    .
  41. S2CID 25728796
    .
  42. PMID 12771076
    .
  43. PMID 3804991
    .
  44. doi:10.1192/apt.bp.107.005090
    .
  45. PMID 17135384
    .
  46. ^
    PMID 9735957
    .
  47. PMID 9497946
    .
  48. ^ Friedberg JM. "Neuroleptic malignant syndrome". Archived from the original on October 16, 2006. Retrieved 2006-07-03. [self-published source]

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Neuroleptic_malignant_syndrome&oldid=1220165415"